Bincy Abraham, MD, MS

home / authors / bincy-abraham-md-ms

Articles

Advice for Physicians to Manage C. Difficile Infection (CDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

October 12th 2022

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Unmet Needs in Management of C. Difficile Infection (CDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

October 12th 2022

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

Differences Between Fecal Microbiota Transplantation Studies to Treat C. Difficile Infection (CDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

October 12th 2022

Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.

SER-109, CP101, VE303 for Treatment of Recurrent C. difficile Infection (rCDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

October 5th 2022

Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

October 5th 2022

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

Challenges with Current Treatments and Emerging Treatments for C. difficile Infection (CDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

September 28th 2022

Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).

Foundational Trials for Fecal Microbiota Transplantation for C. difficile Infection

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

September 28th 2022

Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.

Monitoring Patients with C. difficile Infection (CDI) and rCDI

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

September 21st 2022

Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).

Fecal Microbiota Transplantation (FMT) for Treatment of C. difficile Infection (CDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

September 21st 2022

Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.

Treatment Options for C. difficile Infection (CDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

September 14th 2022

Experts review treatment options for first, second and recurring episodes of Clostridioides difficile infection.

Long-Term Impact of C. difficile Infection (CDI) and Infection Recurrence

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

September 14th 2022

A gastroenterologist reviews long-term impact of dysbiosis and C. difficile infection (CDI).

Gut Microbiota and Consequences of Gut Microbiota Disruption

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

September 7th 2022

Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.

Diagnosis and Management of C. difficile Infection (CDI) in Patients with Inflammatory Bowel Disease

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

September 7th 2022

Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.

Educational Opportunities to Combat C. difficile Infection (CDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

August 31st 2022

Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).

Preventative Measures for C. difficile Infection (CDI

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

August 24th 2022

Dr. Chopra shares multipronged approach to reducing C. difficile infection (CDI) and the role of antimicrobial stewardship.

Timely Referral and Diagnosis of C. difficile Infection (CDI)

Paul Feuerstadt, MD;Thomas Lodise, PharmD, PhD;Teena Chopra, MD, MPH;Bincy Abraham, MD, MS

August 24th 2022

Drs. Abraham, Chopra and Feuerstadt discuss importance of timely referral and diagnostic methods to discern C. difficile infection (CDI).